Skip to main content
. 2019 Jul 9;10(5):1595–1622. doi: 10.1007/s13300-019-0657-8

Fig. 4.

Fig. 4

Overview of trial population and selected cardiovascular endpoints in real-world evidence studies [5356, 94]. This figure reports selected outcomes from four trials and is not a head-to-head trial outcome. CI confidence interval, CVD cardiovascular disease, DPP-4i dipeptidyl peptidase‐4 inhibitor, HF heart failure, HHF hospitalisation for heart failure, HR hazard ratio, oGLD other glucose-lowering drug